Adult Dosing

Vulvovaginitis caused by Candida albicans

• One applicatorful (6 g) intravaginally once or twice daily; continue therapy for 30 days

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Vulvovaginitis caused by Candida albicans

• Hypersensitivity to any of the ingredients of the product or hypersensitivity to sulfonamides

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Use carefully as sulfonamides are absorbed from the vaginal mucosa
• Closely monitor patients for skin rash or evidence of systemic toxicity, and if a rash develops, discontinue therapy
• Oral sulfonamides have been associated with deaths from hypersensitivity reactions, agranulocytosis, aplastic anemia, and other blood dyscrasias
• Oral sulfonamides have rarely been associated with goiter production, diuresis, and hypoglycemia
• Vaginal applicators or inserters should be used with caution in 3rd trimester of pregnancy

Pregnancy Category:C

Breastfeeding: Avoid use in nursing mothers because absorbed sulfonamides may appear in maternal milk and cause kernicterus in the newborn. Because of the potential for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug.

• DERM: Local sensitivity reactions, increased discomfort, burning sensation

• Anti-infective; blocks certain metabolic processes essential for the growth of susceptible bacteria
• Absorption: Unknown
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• AVC

US Availability

AVC

• CRE: 15 %

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Antimicrobials

Vaginal Preparations